english.prescrire.org > Prescrire International > N°267 - February 2025

n°267

February 2025

Issue Contents
Editorial

Free  Take action

p.31

Marketing Authorisations

Mavacamten (Camzyos°) in hypertrophic cardiomyopathy

p.33-36

Dulaglutide (Trulicity°) in type 2 diabetes from 10 years of age

p.36

Eravacycline (Xerava°) in complicated intra-abdominal infections

p.37-38

Atogepant (Aquipta°) in the prevention of migraine attacks

p.38-39

Nivolumab (Opdivo°) in certain melanomas in adolescents

p.39

Dostarlimab (Jemperli°) in advanced or recurrent endometrial cancer with DNA repair defects

p.40-41

Evinacumab (Evkeeza°) in homozygous familial hypercholesterolaemia from 5 years of age

p.41

Lisocabtagene maraleucel (Breyanzi°) in certain relapsed or refractory non-Hodgkin lymphomas

p.42-43

Cipaglucosidase alfa (Pombiliti°) + miglustat (Opfolda°) in late-onset Pompe disease

p.43-44

Etranacogene dezaparvovec (Hemgenix°) in haemophilia B

p.44-45

Oritavancin (Tenkasi°) in skin or soft tissue infections

p.46

Dalbavancin (Xydalba°) in severe bacterial skin or soft tissue infections from 3 months of age

p.47

Adverse Effects

Intravitreal VEGF inhibitors: cardiovascular and renal adverse effects

p.48

Ethinylestradiol + chlormadinone: venous thromboembolism

p.49

Addition of a blood pressure-lowering drug in older patients: falls and fractures

p.49

Metformin: vitamin B12 deficiency

p.50

Amoxicillin: allergic enterocolitis syndrome

p.50

Aripiprazole: pathological gambling

p.51

Common stem: -onide

p.51

Outlook

Free  Towards better patient care: drugs to avoid in 2025

p.52-55

Inset. Main changes in the 2025 update of Prescrire's drugs to avoid

p.54

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe